Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu

Cancer Research

Volumn 60, Issue 3, 2000, Pages 560-565

  Roh, Haeri ^a   Pippin, James ^a   Drebin, Jeffrey A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL;

APOPTOSIS; CASPASE 3; CASPASES; CELL DIVISION; DOWN-REGULATION; HUMANS; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED;

EID: 0033960559     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. r tumour antigen. Nature (Lond.), 312: 513-516, 1984.
2. Coussens, L., Yang-Feng, T. L., Liao, Y-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., and Francke, U. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (Washington DC), 230: 1132-1139, 1985.
3. Yamamoto, T., Ikawa, S., Akiyama, T., Semba, K., Nomura, N., Miyajima, N., Saito, T., and Toyoshima, K. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature (Lond.), 319: 230-234, 1986.
4. Caraway, K. L., and Cantley, L. C. A neu acquaintance for ErbB3 and ErbB4: a role for receptor heterodimerization in growth signaling. Cell, 78: 5-8, 1994.
5. Graus-Porta, D., Beerli, R. R., Daly, J. M., and Hynes, N. E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J., 16: 1647-1655, 1997.
6. Hynes, N. E., and Stern, D. F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochem. Biophys. Acta, 1198: 165-184, 1994.
7. Drebin, J. A., Link, V. C., Stern, D. F., Weinberg, R., and Greene, M. I. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell, 41: 695-706, 1985.
8. Drebin, J., A., Link, V. C., Weinberg, R. A., and Greene, M. I. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc. Natl. Acad. Sci. USA, 83: 9129-9133, 1986.
9. HER2 monoclonal antibodies. Cancer Immunol. Immunother., 37: 255-263, 1993.
10. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol., 14: 737-744, 1996.
11. Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., and Slamon, D. J. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol., 16: 2659-2671, 1998.
12. Pietras, R. J., Pegram, M. D., Finn, R. S., Maneval, D. A., and Slamon, D. J. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene, 17: 2235-2249, 1998.
13. Brodowicz, T., Wiltschke, C., Budinsky, A. C., Krainer, M., Steger, G. G., and Zielinski, C. C. Soluble HER2/neu neutralizes biologic effects of anti-HER2/neu antibody on breast cancer cells in vitro. Int. J. Cancer, 73: 875-879, 1997.
14. Zhang, L., and Hung, M-C. Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Oncogene, 12: 571-576, 1996.
15. Ueno, N. T., Yu, D., and Hung, M-C. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene, 15: 953-960, 1997.
16. Curiel, D. T. Targeted tumor cytotoxicity mediated by intracellular single-chain anti-oncogene antibodies. Adv. Pharmacol., 40: 51-84, 1997.
17. Qian, X. Dougall., W. C., Hellman, M. E., and Greene, M. I. Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation. Oncogene, 9: 1507-1514, 1994.
18. Roh, H., Pippin, J., Boswell, C. B., and Drebin, J. A. Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu. J. Surg. Res., 77: 85-90, 1998.
19. Vaughn, J. P., Iglehart, J. D., Demirdji, S., Davis, P., Babiss, L. E., Caruthers, M. H., and Marks, J. R. Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay. Proc. Natl. Acad. Sci. USA, 92: 8338-8342, 1995.
20. Bertram, J., Killian, M., Brysch, W., Schlingensiepen, K. H., and Kneba, M. Reduction of erbB2 gene product in mammary carcinoma cell lines by erbB2 mRNA-specific and tyrosine kinase consensus phosphorothioate antisense ODNs. Biochem. Biophys. Res. Commun., 200: 661-667, 1994.
21. Colomer, R., Lupu, R., Bacus, S. S., and Gelmann, E. P. erbB-2 antisense ODNs inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. Br. J. Cancer, 70: 819-825, 1994.
22. Crooke, S. T. Advances in understanding the pharmacologic properties of antisense oligonucleotides. Adv. Pharmacol., 40: 1-49, 1997.
23. Stein, C. A. Does antisense exist? Nat. Med., 1: 1119-1121, 1995.
24. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol., 9: 1165-1172, 1989.
25. Rockwell, P., O'Connor, W. J., King, K., Goldstein, N. I., Zhang, L. M., and Stein, C. A. Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA, 94: 6523-6528, 1997.
26. Bates, P. J., Kahlon, J. B., Thomas, S. D., Trent, J. O., and Miller, D. M. Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J. Biol. Chem., 274: 26369-26377, 1999.
27. Ghetie, M. A., Podar, E. M., Ilgen, A., Gordon, B. E., Uhr, J. W., and Vitetta, E. S. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proc. Natl. Acad. Sci. USA, 94: 7509-7514, 1997.
28. 3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res., 55: 2822-2830, 1995.
29. L, and Tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. Clin. Cancer Res., 2: 1215-1219, 1996.
30. Shen, K., and Novak, R. F. Fas-signaling and effects on receptor tyrosine kinase signal transduction in human breast epithelial cells. Biochem. Biophys. Res. Commun., 230: 89-93, 1997.
31. Yu, D., Liu, B., Tan, M., Li, J., Wang, S. S., and Hung, M. C. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene, 13: 1359-1365, 1996.
32. Pegram, M. D., Finn, R. S., Arzoo, K., Beryt, M., Pietras, R. J., and Slamon, D. J. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene, 15: 537-547, 1997.
33. Webb, A., Cunningham, D., Cotter, F., Clarke, P. A., diStefano, F., Ross, P., Corbo, M., and Dziewanowska, Z. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet, 349: 1137-1141, 1997.
34. Stevenson, J. P., Yao, K-S., Gallagher, M., Friedland, D., Mitchell, E. P., Cassella, A., Monia, B., Kwoh, T. J., Yu, R., Holmlund, J., Dorr, F. A., and O'Dwyer, P. J. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A). J. Clin. Oncol., 17: 2227-2236, 1999.
35. Yacyshyn, B. R., Bowen-Yacyshyn, M. B., Jewell, L., Tami, J. A., Bennett, C. F., Kisner, D. L., and Shanahan, W. R. A placebo-controlled trial of ICAM-1 antisense oligodeoxynucleotide in the treatment of Crohn's disease. Gastroenterology, 114: 1133-1142, 1998.
36. Roh, H., Hirose, C. B., Boswell, C. B., Pippin, J. A., and Drebin, J. A. Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents. Surgery, 126: 413-421, 1999.